Bellicum Pharmacueticals Inc. (NASDAQ:BLCM)’s share price shot up 1.8% on Thursday . The stock traded as high as $14.80 and last traded at $14.33, with a volume of 153,207 shares changing hands. The stock had previously closed at $14.07.

Several brokerages have recently weighed in on BLCM. SunTrust Banks Inc. began coverage on shares of Bellicum Pharmacueticals in a report on Thursday, June 2nd. They set a “buy” rating and a $20.00 price objective on the stock. Zacks Investment Research downgraded shares of Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a research report on Thursday, March 17th. Piper Jaffray Cos. reissued a “buy” rating and set a $33.00 target price (down from $45.00) on shares of Bellicum Pharmacueticals in a research report on Monday, March 14th. Finally, Jefferies Group decreased their target price on shares of Bellicum Pharmacueticals from $35.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, March 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $28.00.

The company has a 50 day moving average of $12.22 and a 200-day moving average of $11.61. The firm’s market capitalization is $396.93 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.07. On average, analysts anticipate that Bellicum Pharmacueticals Inc. will post ($2.22) EPS for the current year.

In other Bellicum Pharmacueticals news, CTO Kevin M. Slawin sold 55,000 shares of the firm’s stock in a transaction on Friday, April 22nd. The shares were sold at an average price of $11.43, for a total value of $628,650.00. Following the sale, the chief technology officer now owns 159,206 shares of the company’s stock, valued at approximately $1,819,724.58. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Ken Moseley sold 15,000 shares of the firm’s stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total transaction of $195,000.00. Following the completion of the sale, the vice president now directly owns 15,196 shares in the company, valued at approximately $197,548. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley boosted its position in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, Holdings Channel reports. The firm owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent filing with the SEC.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.